Novartis annual results

Novartis annual results

Investors Annual Results - Cover tab

Annual results 2024 - January 31, 2025

Media release

English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)

Condensed financial report (PDF 0.5 MB)

Webcast and presentation

Watch the webcast

Download the podcast (MP3 30 MB)

Download the presentation (PDF 4.7 MB)

Read the transcript

Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)

Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida

Novartis in Society Integrated Report 2024

This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.

English (PDF 5.0 MB) | German (PDF 4.7 MB)

Prof. Dr. Ulf Landmesser (center) at the Charité hospital in Berlin, Germany

Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024

These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.

Annual Report 2024 (PDF 3.5 MB) |  Form 20-F 2024 (PDF 3.4 MB)

Order the publications

Annual results 2024 - January 31, 2025

Key figures1

Continuing operations2

 FY 2024
(USD m)		FY 2023
(USD m)		% change
(USD/cc)
Net sales50,31745,44011 (cc: 12)
Operating income14,5449,76949 (cc: 55)
Net income11,9398,57239 (cc: 45)
EPS (USD)5.924.1343 (cc: 49)
Free cash flow16,25313,16024

Core		   
Operating income19,49416,37219 (cc: 22)
Net income15,75513,44617 (cc: 21)
EPS (USD)7.816.4721 (cc: 24)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 35 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing corporate activities, and Discontinued operations include operational results from the Sandoz business.

Media release

English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)

Condensed financial report (PDF 0.5 MB)

Watch the webcast

Download the podcast (MP3 30 MB)

Download the presentation (PDF 4.7 MB)

Read the transcript

Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)

Annual results 2023 - January 31, 2024

Key figures1

Continuing operations2

 FY 2023
(USD m)		FY 2022
(USD m)		% change
(USD/cc)
Net sales45,44042,2068 (cc: 10)
Operating income9,7697,94623 (cc: 39)
Net income8,5726,04942 (cc: 62)
EPS (USD)4.132.7749 (cc: 70)
Free cash flow13,16012,1239

Core		   
Operating income16,37214,79411 (cc: 18)
Net income13,44611,94613 (cc: 19)
EPS (USD)6.475.4818 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)

Download 2023 epidemiology data (PDF 1.1 MB)

Annual results 2022 - February 01, 2023

Key figures1FY 2022
(USD m)		FY 2021
(USD m)		% change
(USD/cc)
Net sales50,54551,626-2 (cc: 4)
Operating income9,19711,689-21 (cc: -13)
Net income6,95524,018-71 (cc: -67)
EPS (USD)3.1910.71-70 (cc: -66)
Free cash flow11,94513,282-10

Core		   
Operating income16,66516,5880 (cc: 8)
Net income13,35214,094-5 (cc: 3)
EPS (USD)6.126.29-3 (cc: 6)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)

Annual results 2021 - February 02, 2022

Key figures1FY 2021
(USD m)		FY 2020
(USD m)		% change
(USD/cc)
Net sales51,62648,6596 (cc: 4)
Operating income11,68910,15215 (cc: 13)
Net income24,0188,071198 (cc: 195)
EPS (USD)10.713.55202 (cc: 200)
Free cash flow13,28211,69114

Core		   
Operating income16,58815,4168 (cc: 6)
Net income14,09413,1587 (cc: 5)
EPS (USD)6.295.789 (cc: 7)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Annual results 2020 - January 26, 2021

Key figures2

Continuing operations1

 FY 2020
(USD m)		FY 2019
(USD m)		% change
(USD/cc)
Net sales48,65947,4453 (cc: 3)
Operating income10,1529,08612 (cc: 19)
Net income8,0717,14713 (cc: 20)
EPS (USD)3.553.1214 (cc: 21)
Free cash flow11,69112,937-10

Core		   
Operating income15,41614,1129 (cc: 13)
Net income13,15812,1049 (cc: 12)
EPS (USD)5.785.289 (cc: 13)
  1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Condensed financial report (PDF 0.6 MB)

Source URL: https://prod1.novartis.com/investors/financial-data/annual-results

List of links present in page
  1. https://prod1.novartis.com/investors/financial-data/annual-results
  2. #tabannual-results-16991
  3. #tab2024-17016
  4. #tab2023-17021
  5. #tab2022-17026
  6. #tab2021-17031
  7. #tab2020-17011
  8. https://prod1.novartis.com/node/642611
  9. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-en.pdf
  10. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-de.pdf
  11. https://prod1.novartis.com/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf
  12. https://edge.media-server.com/mmc/p/7vboajm5/
  13. https://prod1.novartis.com/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3
  14. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-investor-presentation.pdf
  15. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript
  16. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf
  17. https://prod1.novartis.com/sites/novartis_com/files/novartis-integrated-report-2024.pdf
  18. https://prod1.novartis.com/sites/novartis_com/files/novartis-integrated-report-2024-de.pdf
  19. https://prod1.novartis.com/sites/novartis_com/files/novartis-annual-report-2024.pdf
  20. https://prod1.novartis.com/sites/novartis_com/files/novartis-20-f-2024.pdf
  21. https://prod1.novartis.com/news/stay-up-to-date
  22. https://prod1.novartis.com/node/642611/printable/print
  23. https://prod1.novartis.com/node/642611/printable/pdf
  24. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-en.pdf
  25. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-de.pdf
  26. https://prod1.novartis.com/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf
  27. https://edge.media-server.com/mmc/p/7vboajm5/
  28. https://prod1.novartis.com/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3
  29. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-investor-presentation.pdf
  30. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript
  31. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf
  32. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-en.pdf
  33. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-de.pdf
  34. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-fr.pdf
  35. https://prod1.novartis.com/sites/novartis_com/files/2024-01-interim-financial-report-en.pdf
  36. https://prod1.novartis.com/sites/novartis_com/files/2024-02/q4-2023-investor-presentation.mp3
  37. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-investor-presentation.pdf
  38. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript
  39. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf
  40. https://prod1.novartis.com/sites/novartis_com/files/novartis-target-patient-populations-2023.pdf
  41. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-en.pdf
  42. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-de.pdf
  43. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-fr.pdf
  44. https://prod1.novartis.com/sites/novartis_com/files/2023-02-interim-financial-report-en.pdf
  45. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-investor-presentation.pdf
  46. https://prod1.novartis.com/sites/novartis_com/files/2023-02/q4-2022-investor-presentation.mp3
  47. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q4-and-full-year-results-transcript
  48. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-february-2023-update.pdf
  49. https://prod1.novartis.com/sites/novartis_com/files/q4-2021-media-release-en.pdf
  50. https://prod1.novartis.com/sites/novartis_com/files/q4-2021-media-release-de.pdf
  51. https://prod1.novartis.com/sites/novartis_com/files/q4-2021-media-release-fr.pdf
  52. https://prod1.novartis.com/sites/novartis_com/files/2022-02-interim-financial-report-en.pdf
  53. https://prod1.novartis.com/sites/novartis_com/files/q4-2020-media-release-en.pdf
  54. https://prod1.novartis.com/sites/novartis_com/files/q4-2020-media-release-de.pdf
  55. https://prod1.novartis.com/sites/novartis_com/files/q4-2020-media-release-fr.pdf
  56. https://prod1.novartis.com/sites/novartis_com/files/2021-01-interim-financial-report-en.pdf